Barclays Initiates Coverage with Overweight Ratings for Stryker and Abbott
Stryker (SYK) and Abbott Laboratories (ABT) saw their stock prices rise on Wednesday after Barclays upgraded both to an Overweight rating as part of its coverage initiation in the MedTech sector. Analyst Christopher Pasquale highlighted these stocks among 26 large-cap medical technology companies, signaling a generally positive outlook for the industry. The move by Barclays reflects confidence in the growth potential and performance of Stryker and Abbott within the healthcare equipment market. The Overweight rating suggests that Barclays believes both stocks are expected to outperform their peers or the broader market over time. This upgrade is likely to attract investor attention, potentially increasing demand for these shares. The MedTech sector has been gaining traction due to ongoing innovation in medical devices and procedures, as well as increased healthcare spending globally.
Topics: Barclays medical technology stock ratings